Engineered virus takes on cancer in first human trial
NCT ID NCT06171178
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested ASP1012, a virus engineered to infect and kill cancer cells while making them visible to the immune system. It was given alone or with the immunotherapy pembrolizumab to 15 adults with advanced solid tumors. The main goals were to check safety and find the right dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASP1012 (an oncolytic virus) and pembrolizumab
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early, first-in-human phase 1 trial with only 15 participants, so safety and effectiveness are not yet known. The trial was terminated, which may indicate challenges.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Gabrail Cancer and Research Center
Canton, Ohio, 44718, United States
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
The Angeles Clinic and Research Institute
Los Angeles, California, 90025, United States
-
University of Iowa Hospitals
Iowa City, Iowa, 52242, United States